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Abstract
The deficiency of Adenosine Deaminase 2 (DADA2) is a new autoinflammatory disease characterised by an early
onset vasculopathy with livedoid skin rash associated with systemic manifestations, CNS involvement and mild
immunodeficiency.
This condition is secondary to autosomal recessive mutations of CECR1 (Cat Eye Syndrome Chromosome Region 1)
gene, mapped to chromosome 22q11.1, that encodes for the enzymatic protein adenosine deaminase 2 (ADA2). By
now 19 different mutations in CECR1 gene have been detected.
The pathogenetic mechanism of DADA2 is still unclear. ADA2 in a secreted protein mainly expressed by cells of the
myeloid lineage; its enzymatic activity is higher in conditions of hypoxia, inflammation and oncogenesis. Moreover
ADA2 is able to induce macrophages proliferation and differentiation; it’s deficiency is in fact associated with a
reduction of anti-inflammatory macrophages (M2). The deficiency of ADA2 is also associated with an up-regulation
of neutrophils-expressed genes and an increased secretion of pro-inflammatory cytokines. The mild
immunodeficiency detected in many DADA2 patients suggests a role of this protein in the adaptive immune
response; an increased mortality of B cells and a reduction in the number of memory B cells, terminally
differentiated B cells and plasmacells has been described in many patients. The lack of the protein is associated
with endothelium damage; however the function of this protein in the endothelial homeostasis is still unknown.
From the clinical point of view, this disease is characterized by a wide spectrum of severity. Chronic or recurrent
systemic inflammation with fever, elevation of acute phase reactants and skin manifestations (mainly represented
by livedo reticularis) is the typical clinical picture. While in some patients the disease is mild and skin-limited, others
present a severe, even lethal, disease with multi-organ involvement; the CNS involvement is rather common with
ischemic or hemorrhagic strokes. In many patients not only the clinical picture but also the histopathologic features
are undistinguishable from those of systemic polyarteritis nodosa (PAN). Of note, patients with an unusual
phenotype, mainly dominated by clinical manifestations suggestive for an immune-disrective condition, have been
described.
Due to its rarity, the response to treatment of DADA2 is still anecdotal. While steroids can control the disease’s
manifestations at high dosage, none of the common immunosuppressive drugs turned out to be effective. Biologic
drugs have been used only in few patients, without a clear effectiveness; anti-TNF drugs are those associated to a
better clinical response. Hematopoietic stem cells transplantation was effective in patients with a severe phenotype.
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Background
The deficiency of Adenosine Deaminase 2 (DADA2)
is a recently identified disease, gathered in the family
of autoinflammatory diseases, mainly characterised by
early-onset polyarteritis, hemorrhagic and ischemic
strokes and hypogammaglobulinemia.
In February 2014 two independent studies, one held
by the American National Institutes of Health in Be-
thesda [1] and the other one by the Israeli Sharee Zedek
Medical Center in Jerusalem [2], identified this new clin-
ical entity, often familial, characterised by early onset
livedoid rash associated with systemic inflammation
(fever and elevation of acute phase reactants). Some pa-
tients presented ischemic or haemorrhagic cerebral
stroke, other vasculopathy-related manifestations (hyper-
tension, gastrointestinal symptoms), hepatosplenome-
galy, peripheral neuropathy and mild immunodeficiency.
In many cases both the clinical manifestations and the
histological findings were consistent with the diagnosis
of polyarteritis nodosa (PAN), with childhood-onset.
The analysis of the whole exome-sequencing (WES) in
unrelated affected patients identified autosomal recessive
deleterious mutations in CECR1 gene, encoding for ad-
enosine deaminase 2 (ADA2).
The marked reduction of both plasmatic levels and
enzymatic activity of ADA2 detected in affected pa-
tients respect to healthy donors [1, 2], confirmed the
hypothesis that the causative mutation determines the
loss-of-function of the protein. The non-affected simple-
heterozygous parents displayed intermediate values of
both plasmatic levels and enzymatic activity [1].
CECR1 gene
The CECR1 (Cat Eye Syndrome Chromosome Region 1)
gene, mapped to chromosome 22q11.1 and constituted
by 10 exons [1, 2], encodes for the enzyme adenosine
deaminase 2 (ADA2), a protein composed by 4 domains:
the signal sequence, the dimerization domain, the puta-
tive receptor-binding domain and the catalytic domain.
The mutations detected in CECR1 gene so far are 19,
with a different prevalence according to patient’s ethni-
city (Table 1, Fig. 1) [1–13]. The G47R mutation has
been detected in homozygous state in all patients of
Georgian Jewish and Turkish origin. Based on the results
of the molecular analysis performed in 246 healthy do-
nors of Georgian Jewish origin, the estimated frequency
of this mutation in this population is 10 % [2].
Table 1 CECR1 mutations so far detected
Mutation Exon HGVS sequence name Aminoacid substitution N° of patients Enzymatic domain
M1T 2 c.2 T > C Met1Thr 1 in compound heterozygosis Signal peptide
K13del 2 c.37_39del 37_39del 2 in compound heterozygosis Signal peptide (?)
28-kb-deletion 2 deletion deletion 1 in compound heterozygosis 5′UTR (5′untranslated region)
G47R 2 c.139G > A Gly47Arg 27 in homozygosis Dimerization
1 in compound heterozygosis
G47A 2 c.140G > C Gly47Ala 2 in compound heterozygosis Dimerization
G47V 2 c.140G > T Gly47Val 1 in compound heterozygosis Dimerization
I93T 2 c.278 T > C Ile93Thr 1 in compound heterozygosis Dimerization
A109D 3 c.326C > A Ala109Asp 1 in compound heterozygosis Catalytic
H112Q 3 c.336C > G His112Gln 1 in compound heterozygosis Catalytic
T119A 3 c.355A > G Thr119Ala 4 in compound heterozygosis Catalytic
G142S 3 c.424G > A Gly142Ser 4 in compound heterozygosis Catalytic
R169Q 3 c.506G > A Arg169Gln 15 in homozygosis PBR (putative receptor-binding)
9 in compound heterozygosis
P193L 4 c.578C > T Pro193Leu 1 in compound heterozygosis Catalytic (?)
M243R 4 NA Met243Arg 2 in compound heterozygosis Catalytic
P251L 4 c.752C > T Pro251Leu 4 in compound heterozygosis Catalytic
W264S 5 c.791G > C Trp264Ser 1 in compound heterozygosis Catalytic
R306* 6 c.916C > T p.Arg306* 1 in compound heterozygosis Catalytic (?)
N328K 7 c.1159C > A Cys1159Arg 2 in compound heterozygosis Catalytic
Y453C 9 c.1358A > G Tyr453Cys 3 in compound heterozygosis Catalytic
Legend: HGVS: Human Genome Variation Society
NA not available
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Conversely, the R169Q is the mutation more fre-
quently detected in the European Caucasian population
[1, 2, 7, 12, 13].
The mutations so far detected affect the Signal peptide
(n = 2), the 5’ untranslated region (n = 1), the
dimerization domain (n = 4), the putative receptor bind-
ing (n = 1) and the catalytic domain (n = 11) (Table 1,
Fig. 1) [1–13]. Moreover two patients with a homozy-
gous deletion on 22.11.1 chromosome (encompassing
CECR1 gene) have been recently described [14].
ADA2 protein and pathogenetic mechanisms
The enzyme Adenosine Deaminase (ADA) plays a key
role in the purine metabolism converting adenosine to
inosine and 2′-deoxyadenosine to 2′-deoxyinosine [15].
The two major ADA isoforms are ADA1, whose defi-
ciency is cause of a severe combined immunodeficiency
(SCID) [16], and ADA2.
Even if the two proteins have partial structural hom-
ology, the two isoenzymes differ in many aspects: the af-
finity of ADA2 for molecules of adenosine and deoxy-
adenosine is about 100 times lower than that of ADA1;
consequently, at physiological concentrations of sub-
strate, the deaminase activity of ADA2 is almost absent
[17].
While ADA1 is monomeric and acts primarily intra-
cellularly, ADA2 is dimeric and secreted in the extracel-
lular environment where it exerts its main functions. For
this reason ADA2 is clearly detectable in the plasma.
Finally, while ADA1 is ubiquitally expressed in all cell
types, ADA2 is mostly expressed by monocytes and
other cells of the myeloid lineage [17].
ADA2 is more stable at high temperatures and the
optimum pH for its activity is generally acid (about 6.5),
which suggests a specialized role of this enzyme in
conditions of hypoxia, inflammation and oncogenesis; in
these conditions its deaminase activity is higher [17]
(Fig. 2).
The capacity of binding receptors involved in the sig-
nal transduction of different pathways (such as proteo-
glycans), confers to ADA2 a growth-factor like action;
for this reason ADA2 is considered an Adenosine
Deaminase-related Growth-Factor (ADGF) [17–19]
(Fig. 2).
ADA2 displays also an autocrine activity: the protein,
released by activated monocytes, is able to induce mono-
cyte proliferation and macrophage differentiation [20];
CECR1 silencing in myeloid cells is in fact associated to
a reduced differentiation of monocytes to macrophages
[1]. This activity has been demonstrated to be mediated
by the direct binding of cellular receptors, and therefore
to be independent from the enzymatic activity [20]
(Fig. 2).
ADA2 seems to be also involved in the balance be-
tween pro-inflammatory (M1) and anti-inflammatory
(M2) monocytes; its absence has been in fact associated
with a defect in differentiation of M2 macrophages,
which leads to a prevalence of pro-inflammatory M1
cells [1].
Microarray analysis in two DADA2 patients showed a
marked up-regulation of neutrophils-expressed genes.
Intracellular staining revealed an increased expression of
myeloperoxidase (MPO) in peripheral blood mono-
nuclear cells compared to controls [8] (Fig. 2). Accord-
ing with these findings, the assessment of cytokine levels
performed in the serum of few described patients re-
vealed an increase of pro-inflammatory cytokines: in the
two patients carrying a homozygous deletion of 22q11.1
chromosome increased levels of both IL-1β and TNFα
were detected [14], while in another case the detection
Fig. 1 Cat Eye Syndrome Chromosome Region 1 (CECR1) gene and Adenosine Deaminase 2 (ADA2) protein with the mutations by now detected
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of IL-6 revealed increased levels [7]. These data are in
contrast with the results obtained in the NIH study, in
which the cytokine assay performed in the supernatants
of the whole blood cell cultured with different stimuli
did not reveal any significant difference between pa-
tients and healthy donors [1]. Further studies on lar-
ger series of patients are therefore needed in order to
investigate the cytokines’ pattern in DADA2; in par-
ticular the cytokines’ production should be assessed
in stimulated PBMCs and should take into consider-
ation the disease activity.
It has been also postulated that the deregulation of
purinergic stimulation, due to the decrease of the en-
zymatic activity of ADA2, may play a pro-inflammatory
role. Adenosine is in fact an important signaling mol-
ecule that can modulate the inflammatory response; its
concentration in tissues is normally low and increases in
condition of cellular stress, ischemia or inflammation
[21]. The accumulation of adenosine can influence the
inflammatory response by binding several receptors that
lead to inflammation, tissue damage and fibrosis [21].
However, the plasmatic levels of adenosine and deoxia-
denosine in few DADA2 patients has been detected
within the normal range [1, 2].
Since hypogammaglobulinemia has been described in
some patients, adaptive immunity has been investigated
in ADA2 patients. A reduction in the number of mem-
ory B cells, terminally differentiated B cells and plasma-
cells has been described [1, 7]; moreover co-culture
experiments have enlightened an increased mortality of
B cells [1]. Not univocal results have been detected con-
cerning the T cells function. In fact, while in the NIH
study ADA2 mutations seem not to affect T lymphocyte
number and activation [1], in a more recent study an in-
crease of regulatory T cells and a decrease of CD8+ and
CD4 +memory T cells have been detected in one patient
Fig. 2 Production and physiological role of Adenosine Deaminase 2 (ADA2). ADA2 is produced and secreted by cells of myeloid lineage; it exerts its
enzymatic activity in the extracellular space, especially in the presence of a low pH or high temperature. On monocytes (a) ADA2 acts as growth-factor
with an autocrine activity: it induces monocytes’ proliferation and promote the differentiation of M2 anti-inflammatory macrophages. On neutrophils
(b) ADA2 induces the gene of expression of some pro-inflammatory proteins, such as myeloperoxidase (MPO) and neutrophils’ activations, leading to
the secretion of pro-inflammatory cytokines. There are indirect evidences of a possible role of ADA2 as growth-factor for endothelial cells (c)
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with DADA2 [7]. In addition a reduced number of Th1,
Th2 and follicular T helper (Tfh) cells has been observed
in the same patient.
The reason why endothelium represents the main tar-
get of inflammation in DADA2 is still largely unknown.
ADA2 acts as a growth-factor for endothelial cells. In
fact, even if it has been demonstrated that endothelial
cells do not express CECR1 gene, the deficiency of
ADA2 is associated to a damage of vascular endothelium
and to an over expression of activation markers [1]. The
knockdown animal model for CECR1 gene (zebrafish)
displays cerebral haemorrhages without morphologic al-
teration in the vascular structure; these episodes recov-
ered following the transfection of non-mutant human
CECR1 messenger RNA [1]. In the same way, monocytes
of patients with DADA2 led to destruction of co-
cultured human microvascular endothelial cells [1].
Due to the rarity of the disease, all available data on
the pathogenic consequences of ADA2 defect in humans
come from few patients; further studies are therefore
needed in order to better enlighten the activity of ADA2
in the innate and adaptive immune response and its role
in the endothelium homeostasis.
Clinical manifestations
DADA2 can be defined as an inflammatory vasculopathy
with a wide range of clinical manifestations, possibly as-
sociated with an immunodeficiency of variable severity.
The disease is mainly characterized by chronic or recur-
rent systemic inflammation with fever and elevation of
acute phase reactants, usually associated with different pos-
sible skin manifestations, ranging from the most frequent
livedo reticularis (Fig. 3) to maculopapular rash, nodules,
purpura, erythema nodosum, Raynaud’s phenomenon, ul-
cerative lesions, digital necrosis [1, 2].
The clinical picture is wide, ranging form a mild dis-
ease with a late onset skin-limited involvement to a very
severe systemic phenotype (even fatal) with an early on-
set and a multi-organ involvement (Tables 2 and 3).
In most patients, a neurological involvement, affecting
both the peripheral and central nervous system, has
been described.
The severity of the CNS involvement is rather variable.
In some patients a transitorily ischemic attack (TIA) has
been described (with negative cerebral CT and/or MRI),
while others developed an ischemic or hemorrhagic stroke
(in few cases a ventricular haemorrhage has also been de-
tected). Typically, the strokes associated to DADA2 are la-
cunar with a wide range of clinical manifestations ranging
from clinically silent episodes in few cases, to severe ones
leading to a permanent disability [1, 2, 10, 12].
The neuropathy ranges from a transient mononeuritis
(such as a cranial nerve transient paralysis) to a perman-
ent polyneuropathy; moreover, few patients suffered
from optic neuritis. In few cases, persistent neurosensor-
ial hearing loss has also been described [1, 2, 12].
Most patients have gastrointestinal manifestations: ab-
dominal pain, significant weight loss, chronic gastritis,
hepatomegaly, splenomegaly, portal hypertension, bowel
perforation or stenosis.
While nephrogenic hypertension is rather common in
this condition, in few patients focal glomerulosclerosis
and renal amyloidosis have also been described [11].
Lung involvement with necrotising pneumonia (lethal)
has been reported in one patient [11].
The blood tests usually reveal an elevation of acute
phase reactants (ERS, CRP), low haemoglobin levels and
neutrophilic leukocytosis [1, 2]; however in few patients
cytopenia (pancytopenia, leucopoenia) has been detected
[1, 7, 12]. Auto-antibody are usually negative.
As stated above, a mild immunodeficiency can be ob-
served; some patients present hypogammaglobulinemia
that may affect IgM or all Ig subclasses [1, 13]. Of note,
despite the low immunoglobulins’ levels, only few cases
displayed an increased susceptibility to infections, that
was rather severe in exceptional cases [1, 3, 7, 12, 13].
MRI is the most useful tool in the diagnosis of cerebral
strokes; in fact CT scan as well as conventional angiog-
raphy may not detect the smaller lacunar strokes and
therefore underestimate the entity of involvement of the
CNS [1].
Some patients underwent an angiographic investiga-
tion, that revealed the presence of stenosis and/or aneu-
rysms of abdominal artery, particularly mesenteric,
celiac, hepatic and renal arteries; the histological ana-
lysis, when done, revealed a necrotizing vasculitis [1, 2].
In patients with symptoms suggestive for organ in-
volvement but without pathologic finding in not-invasive
radiologic studies, conventional angiography can be of
help revealing aneurism and or stenosis in the middle
sizes arteries.
Fig. 3 Livedo reticularis in a patient with DADA2
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Fever Skin CNS/PNS Gastro-intestinal Immune/
Hematologic system
ANA ANCA Hypertension Other
Navon et al. 1 G47R/G47R Georgian 2 m Yes Ulcerations at
extremities
No Intestinal necrosis No neg neg Yes Coronary
aneurysms




No Intestinal vasculitis No neg neg No No








No No neg neg Yes Arthritis








No No pos ND No No




No No neg neg No Arthritis
6 G47R/G47R Georgian 2 m (died at
9 m)




No neg neg No No




No Abdominal pain No neg ND No No





No Abdominal pain No neg neg No No
9 G47R/G47R Georgian 9 y No Livedo reticularis No No No neg neg No No






No No No neg neg No No
11 G47R/G47R Georgian 59 y No Leg ulcers No No No neg ND No No
12 G47R/G47R Georgian childhood

















Table 2 Clinical manifestation of DADA2 patients so far described (Continued)
leg ulcers with
amputation







No No neg neg No No




No No No pos ND No No
15 G47R/G47R Georgian 1 y Yes Livedo reticularis No Abdominal pain No neg neg Yes Mesenteric and
renal infarcts
16 G47R/G47R Georgian 18 y No No No No No neg neg No No






Polyneuropathy No No neg neg Yes Panniculitis
18 G47R/G47R Georgian 2 y No Skin nodules Polyneuropathy No No neg neg No No




No No No pos neg Yes No
20 R169Q/P251L European
Caucasian
1 y Yes Livedo reticularis Ischemic stroke,
cranial nerves
(II,VI,VII) paralysis
No No neg ND Yes No
21 R169Q/P251L European
Caucasian
12 y No No Ischemic stroke,
VII cranial nerve
paralysis
No No pos neg No No
22 R169Q/P251L European
Caucasian









No No neg neg No No
23 R169Q/P251L European
Caucasian








No No ND ND No Epididymitis













Table 2 Clinical manifestation of DADA2 patients so far described (Continued)
Zhou et al. 1 A109D/Y453C European
Caucasian
2 y Yes Livedo reticularis Ischemic stroke Splenomegaly No pos neg No No
2 G47A/Y453C European
Caucasian



























Leucopoenia, hypoIg neg neg No No
4 G47A/H112Q European
Caucasian











neg neg No No
5 R169Q/Y453C European
Caucasian
1,5 y Yes Livedo reticularis Ischemic stroke Hepatomegaly,
splenomegaly.











No neg neg Yes Evans syndrome







No No neg neg No No




Ischemic stroke Bowel perforation No neg neg No Macrophage
activation
syndrome


















NA NA No No




NA NA No No
Bras et al. 1 T119A/G142S European
Caucasian




Stroke No No NA NA No No
2 T119A/G142S European
Caucasian















Table 2 Clinical manifestation of DADA2 patients so far described (Continued)
3 T119A/G142S European
Caucasian




Stroke No No NA NA No No
4 T119A/G142S European
Caucasian




Stroke No No NA NA No No
Van Eyck
et al.




Garg et al. 1 G47R/R306* Turkish 1,5 y (died 5
y)

















NA NA No No
2 R169Q/R169Q African/
Caucasian
5 m No No TIA Bowel perforation
(ulcerative bowel






NA NA No No
Belot et al. 1 R169Q/P193L European
Caucasian









Bowel stenosis HypoIg neg neg No Oral aphtae






















No No NA NA No No
2 R169Q/R169Q European
Caucasian






2 y Yes Livedo
racemosa
No No HypoIg NA neg No No
2 K13del/N328K European
Caucasian




No No HypoIg, recurrent
infections











Table 2 Clinical manifestation of DADA2 patients so far described (Continued)
Batu et al. 1 G47R/G47R Turkish 6,5 y Yes Livedo
reticularis,
No Abdominal pain No NA NA No No







No pos NA Yes Glomerulosclerosis












































neg neg No No
4 R169Q/R169Q European
Caucasian













neg neg No No
5 R169Q/R169Q European
Caucasian





neg ND No Autism
6 R169Q/R169Q European
Caucasian





























neg neg No No
9 R169Q/R169Q African/
Caucasian






























No No Recurrent infection
(C. Albicans, S.
aureus), neutropenia



















NA 18 y No No No Splenomegaly HypoIg, recurrent
respiratory infections
NA NA No Arthralgia
2 R169Q/
M243R











neg NA No Arthritis
Failure to thrive.
Legend: CNS central nervous system
PNS peripheral nervous system















Table 3 genotype/phenotype correlation in DADA2
Mutation Exon N° of patients Associated symptoms (% of patients)
M1T 2 1 in heterozygosis Fever
Skin: Non-Langerhans cell histiocytosis
CNS/PNS: ischemic stroke
Visceral: involvement: hepatomegaly, splenomegaly. portal hypertension, hypertension (100 %)
K13del 2 2 in heterozygosis Fever (50 %)
Skin: Livedo racemosa (50 %), skin nodules (50 %)
Immune/hematologic system: hypogammaglobulinemia (100 %), recurrent infections (50 %)
28-kb-deletion 2 1 in heterozygosis Fever
Skin: Livedo reticularis, urticarial rash
CNS/PNS: ischemic and haemorrhagic strokes
Visceral involvement: hepatomegaly, splenomegaly. chronic gastritis
Immune/hematologic system: leukopenia, hypogammaglobulinemia (100 %)
G47R 2 27 in homozygosis Fever (64 %)
Skin: Livedo reticularis (60 %), skin nodules (35 %), ulcerations at extremities/digital necrosis (32 %), Raynaud’s
phenomenon (28 %), purpuric/vasculitic rash (18 %), erythema nodosum (18 %), panniculitis (3 %)
CNS/PNS: ischemic stroke (21 %), hemorrhagic stroke (7 %), intracranial haemorrhage (11 %), cranial nerve
paralysis (14 %), polineuropathy (11 %), neurosensorial hearing loss (3 %).
Visceral involvement: abdominal pain (21 %), intestinal vasculitis (14 %), hepatomegaly (3 %),
splenomegaly (7 %), hypertransaminasemia (3 %), hypertension (25 %).
Immune/hematologic system: Leucopoenia (3 %), anaemia (3 %), lymphadenopathy (3 %).
1 in heterozygosis
G47A 2 2 in heterozygosis Fever (100 %)
Skin: Livedo reticularis (100 %), urticarial rash (100 %)
CNS/PNS: ischemic and haemorrhagic strokes (100 %)
Visceral involvement: hepatomegaly (100 %), splenomegaly (100 %), portal hypertension (100 %)
Immune/hematologic system: Pancytopenia (100 %), hypogammaglobulinemia (100 %).
G47V 2 1 in heterozygosis Fever
Skin: Livedo reticularis
Visceral involvement: hypertension, abdominal and renal aneurysm (100 %).
I93T 2 1 in heterozygosis Fever
Skin: Non-Langerhans cell histiocytosis
CNS/PNS: ischemic stroke
Visceral: involvement: hepatomegaly, splenomegaly. portal hypertension, hypertension (100 %)
A109D 3 1 in heterozygosis Fever
Skin: Livedo reticularis
CNS/PNS: ischemic stroke
Visceral involvement: splenomegaly (100 %).
H112Q 3 1 in heterozygosis Fever
Skin: Livedo reticularis, urticarial rash
CNS/PNS: ischemic and haemorrhagic strokes
Visceral involvement: hepatomegaly, splenomegaly, portal hypertension
Immune/hematologic system: Pancytopenia, hypogammaglobulinemia (100 %).
T119A 3 4 in heterozygosis Fever (100 %)
Skin: Livedo reticularis, ulceration of extremities (100 %)
CNS/PNS: ischemic and haemorrhagic strokes (100 %)
G142S 3 4 in heterozygosis Fever (100 %)
Skin: Livedo reticularis, ulceration of extremities (100 %)
CNS/PNS: ischemic and haemorrhagic strokes (100 %)
R169Q 3 15 in homozygosis Fever (37 %)
Skin: Livedo reticularis (58 %), skin nodules (4 %), ulcerations at extremities/digital necrosis (8 %),
Raynaud’s phenomenon (8 %), purpuric/vasculitic rash (13 %), erythema nodosum (13 %), eczema (20 %)
CNS/PNS: ischemic stroke (54 %), hemorrhagic stroke (13 %), intracranial haemorrhage (13 %), cranial
nerve paralysis (37 %), polineuropathy (8 %), neurosensorial hearing loss (8 %).
Visceral involvement: abdominal pain (17 %), bowel ulcerations (8 %), chronic gastritis (4 %), bowel stenosis
(4 %), colitis (4 %), hepatomegaly (45 %), splenomegaly (58 %), acute liver failure (4 %), hypertension (8 %).
Immune/hematologic system: hypogammaglobulinemia (62 %), pancytopenia (8 %), leucopoenia (20 %),
lymphopenia (13 %), granulocytopenia (4 %), anaemia (25 %), thrombocytopenia (4 %),
lymphadenopathy (25 %), recurrent infections (29 %).
9 in heterozygosis
P193L 4 1 in heterozygosis Fever
Skin: Livedo reticularis, ulcerations at extremities
CNS/PNS: ischemic stroke, TIA, intracranial haemorrhage, polineuropathy
Visceral involvement: bowel stenosis, oral aphtae
Immune/hematologic system: hypogammaglobulinemia (100 %).
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Skin biopsy revealed, in most cases, a non-
granulomatous, necrotizing vasculitis of small and
medium-sized vessels, with the same histopathologic fea-
tures of polyarteritis nodosa [1, 2, 9].
In few cases the histology was less specific showing a
leucocytoclastic vasculitis or a panniculitis.
Polyarteritis nodosa (PAN) is, according to the Chapel
Hill classification, a “Necrotizing arteritis of medium or
small arteries without glomerulonephritis or vasculitis in
arterioles, capillaries, or venules, and not associated with
antineutrophil cytoplasmic antibodies (ANCAs)” [22].
It’s gathered in the medium-sized vessels vasculitis, even
if it can affect arteries of any size [22].
Being DADA2 a vasculitis with a genetic basis, it has
been proposed to group this disease in the vasculitis
with a probable cause according to the Chapel Hill clas-
sification [11, 22].
Notably, most of the DADA2 patients not only re-
ceived the histological diagnosis of PAN but also met
the EULAR/PRINTO/PRES diagnostic criteria for child-
hood polyarteritis nodosa (Table 4) [23].
Unusual phenotypes
Even if most of the patients with DADA2 have a clinical
phenotype consistent with a systemic inflammatory vas-
culopathy, a recent report has enlighten that the disease
may be dominated by clinical manifestations suggestive
for an immune-disrective condition, such as cytopenia,
lymphadenopathy, hepatosplenomegaly and immuno-
deficiency with severe viral infections [7]. The two pa-
tients described did not present skin involvement and
one of them developed a vascular involvement only after
bone-marrow transplantation. Of note, the mutations
found in these two patients were the same described in
patients with a “typical” inflammatory clinical picture.
Similarly a third patient with a lymphoprolipherative
clinical picture, resembling Castleman’s syndrome, has
been reported by the same group [5].
Table 3 genotype/phenotype correlation in DADA2 (Continued)
M243R 4 2 in heterozygosis Fever (50 %)
Skin: erythema nodosum (50 %)
CNS/PNS: intracranial haemorrhage (50 %)
Visceral involvement: splenomegaly (100 %)
Immune/hematologic system: hypogammaglobulinemia (100 %), recurrent infections (100 %).
P251L 4 4 in heterozygosis Fever (25 %)
Skin: Livedo reticularis (75 %), vasculitic rash (50 %)
CNS/PNS: ischemic stroke (75 %), cranial nerve paralysis (100 %), neurosensorial hearing loss (25 %).
Visceral involvement: hypertension (25 %), epididymitis (25 %)
W264S 5 1 in heterozygosis Fever
Skin: Livedo reticularis
Visceral involvement: hypertension, abdominal and renal aneurysm (100 %).
R306* 6 1 in heterozygosis Fever
Skin: rash
CNS/PNS: ischemic stroke, hemorrhagic stroke, intracranial haemorrhage (100 %)
N328K 7 2 in heterozygosis Fever (50 %)
Skin: Livedo racemosa (50 %), skin nodules (50 %)
Immune/hematologic system: hypogammaglobulinemia (100 %), recurrent infections (50 %)
Y453C 9 3 in heterozygosis Fever (100 %)
Skin: Livedo reticularis (100 %), urticarial rash (33 %)
CNS/PNS: ischemic stroke (100 %), haemorrhagic strokes (33 %)
Visceral involvement: hepatomegaly (66 %), splenomegaly (100 %), portal hypertension (33 %)
Immune/hematologic system: Pancytopenia (66 %), hypogammaglobulinemia (66 %).
Table 4 EULAR/PRINTO/PRES classification criteria for childhood Polyarteritis nodosa (PAN) [23]
Histopathology or angiographic abnormalities
(mandatory) plus one of the five following criteria:
- Histology: necrotising vasculitis in medium
or small-sized arteries.
- Angiography: aneurysm, stenosis or
occlusion of a medium or small sized artery,
EULAR/PRINTO/PRES classification criteria for
childhood Polyarteritis nodosa (c-PAN)
1. Skin involvement Livedo reticularis, skin nodules, superficial
ulcers, peripheral tissue necrosis
2. Myalgia/muscle tenderness Muscle pain or tenderness
3. Hypertension Blood pressure > 95th centile
4. Peripheral neuropathy Sensory or motor neuropathy
5. Renal involvement Proteinuria, haematuria, impaired function
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A more recent clinical series of 9 DADA2 patients
with the homozygous R169Q mutation has enlightened
that the presence of cytopenia is a common finding of
the disease, together with the common inflammatory
manifestations [12].
In the two patients carrying homozygous 22q11.1 dele-
tion, encompassing both copies of the IL-17 receptor A
(IL17RA) and the CECR1 gene, the clinical phenotype
was dominated by muco-cutaneous infections and
dermatitis associated to persistent inflammation and, in
one patient, vasculitis responding to steroids [14]. Livedo
reticularis, stroke and other DADA2 clinical manifesta-
tions were not described.
Finally two brothers with a clinical picture consistent
with the diagnosis of common variable immunodefi-
ciency (CVID) were found to be affected by DADA2 by
whole exome-sequencing; of note only one of them dis-
played clinical sign and symptoms consistent with a vas-
culopathy [13].
Outcome
Being a disease of recent identification, the clinical out-
come has not been well investigated. However, from the
clinical data by now available is clear that the spectrum
of severity of the disease is wide, ranging from patients
with neonatal onset and a severe organ involvement to
patients with onset in the adulthood and the presence of
only skin manifestations (Tables 2 and 3); of note, even
between patients carrying the same mutations in CECR1
gene the clinical picture can be widely different (Tables 2
and 3).
The disease turned out to be lethal in seven out of the
65 patients by now described [1, 2, 6, 13, 14]: in three
cases the severity of the visceral involvement was lethal
[1, 2], two patients died for respiratory complications
following intracranial haemorrhage [6, 13], while one pa-
tient developed necrotising pneumonia [1, 11]; finally
one of the two patients carrying the homozygous dele-
tion on 22.11.1 chromosome died for septic shock.
Treatment
DADA2 is a newly recognised condition and the number
of patients so far described is limited; for this reason the
response to treatment is largely anecdotal and still con-
troversial (Table 5).
Being an inflammatory condition, high doses of ste-
roids are usually able to control the clinical manifesta-
tions [1, 2, 8, 9, 11, 12]. However, due to the severity of
the condition, a steroid-dependence is often described.
None of the most common immunosuppressive drugs
(cyclophosphamide, azathioprine, methotrexate) was ef-
fective [1, 2, 6, 8, 11, 13].
Navon et al. reported ten patients treated with anti-
TNF drugs (etanercept, adalimumab, infliximab) with
complete response in 8, even after the failure of im-
munosuppressive therapies [2]; good results with anti-
TNF agents were also reported in other small series
[3, 11, 12]. By now, the reason why this drug is effect-
ive is still unclear.
According to the report of Zhou et al., neither im-
munosuppressive nor biologic drugs were able to
completely control the disease manifestations in all
treated patients; the enzymatic substitutive treatment
(fresh frozen plasma or recombinant enzyme) was
postulated to be of help. This approach was tempted
in two patients reported by Batu et al. with a transi-
ent good response in one and a not-satisfactory re-
sponse in the other [11].
A possible role of hematopoietic stem cell trans-
plantation (HSCT) has been postulated to be effective
by Zhou et al. and Navon et al., being able to provide
ADA2 producing monocytes and therefore to
normalize the plasmatic levels of the enzyme [1, 2].
This therapeutic strategy, performed in one of the
two patients reported by Van Eyck et al. [7] and in a
patient reported by the NIH group [3], was able to
normalize the plasmatic levels of ADA2 and to con-
trol the disease manifestations [3, 7]; early complica-
tions occurred in one of them. More recently two
additive patients who displayed a complete response
to HSCT have been described [12].
Van Eyck et al. conclude that HSCT should be sug-
gested only for those patients with a severe disease, since
DADA2 patients present an increased risk of HSCT-
related complications due to the persistent inflammation
and the compromised endothelial integrity [7]. Of note,
the other patient described in this paper displayed a
complete response to treatment with sirolimus; the au-
thors assume that this drug may be of help in the con-
trol of the clinical manifestations related to ADA2-
deficiency, being able to reduce the M1 macrophage dif-
ferentiation and the production of IL-6 [7].
Conclusion
In conclusion DADA2 is a genetic condition mainly
characterized by an inflammatory vasculopathy resem-
bling polyarteritis nodosa (PAN). From the clinical data
so far available, the age at onset, the disease manifesta-
tions and severity are widely variable. Further clinical
studies are therefore needed in order to better under-
stand the phenotypic viability of this condition and the
genotype-phenotype correlation.
In light of the data by now available, we consider
the genetic analysis of CECR1 gene suggested in the
following clinical pictures: patients with an inflammatory
vasculopathy with early onset in infancy, patients with a
diagnosis of PAN or cPAN with early onset and/or severe
organ involvement (above all stroke), especially in case of
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Table 5 Treatment administrated and clinical response in the described DADA2 patients (1-14)
Therapy Case report
(number of treated patients)
Response to treatment
Steroids (orally or i.v.) Navon et al. (17) In 2 cases complete control of the disease with on demand steroidal therapy.
In other patients steroid-dependence.
Zhou et al. (9) Partial control of diseases manifestations with high doses of corticosteroids
Van Eyck et al. (2) Steroid-dependence
Belot et al. (2) Steroid-dependence
Garg et al. (1) Steroid-dependence
Van Montfrans et al. (6) Partial response in 3 patients
Schepp et al. (1) Partial response
cyclophosphamide (orally or i.v.) Navon et al. (9) Good response in 2 patients.
Zhou et al. (7) Not specified
Belot et al. (2) Partial response
Garg et al. (1) Poor response
Batu et al. (4) Poor response
Azathioprine Navon et al. (7) No patients with complete response
Van Eyck et al. (2) Poor response
Belot et al. (1) Good response in association to methotrexate
Batu et al. (3) Poor response
Van Montfrans et al. (5) Not specified
Methotrexate Navon et al. (3) Good response in association with other immunosuppressive and biologics
Belot et al. (1) Good response in association with azathioprine
Batu et al. (3) Poor response
Schepp et al. (1) Partial response
Cyclosporine Van Eyck et al. (1) Poor response
Colchicine Batu et al. (5) Good response in one patient, none response in 4 patients
Mycophenolate Zhou et al. (2) Not specified
Van Eyck et al. (1) Poor response
Belot et al. (1) Partial response in association with cyclophosphamide
Batu et al. (2) Good response in one patient, poor in the other
Sirolimus Van Eyck et al. (2) Good response in one patient
Poor response in one patient
Tacrolimus Van Eyck et al. (2) Good response in one patient
Poor response in one patient
I.v. immunoglobulins Navon et al. (1) Not specified
Zhou et al. (5) Not specified
Van Eyck et al. (2) Prophylactic dosage
Belot et al. (1) Prophylactic dosage
Schepp et al. (2) Prophylactic dosage
Anakinra Zhou et al. (5) Not specified
Garg et al. (1) Initial partial response than relapse
Van Montfrans et al. (1) Good response
Canakinumab Garg et al. (1) Initial partial response than relapse
Etanercept Navon et al. (5) Complete response in 5 patients
Partial response in 1 patient
Zhou et al. (6) Not specified
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a positive family history or consanguinity/endogamy in
the parents. Moreover DADA2 should be ruled out in pa-
tients with an immune-disreactive condition without an
underlying diagnosis, especially in presence of signs or
symptoms of vasculitis.
Finally, a better enlightenment of the pathogenetic
mechanisms of the disease is needed; these data will be of
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van Montfrans et al. (3) Partial response in 1 pateint
Complete response in 2 patients
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Adalimumab Navon et al. (3) Complete response in 2 patients, exacerbation in 1 patient
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Belot et al. (1) Poor response
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